Table 2
Trial characteristics of the comparisons
| Trial characteristics | Trials blinded for ~ | Trials unblinded for ~ |
|---|---|---|
| Participants | ||
| Funding sources | ||
| Industry | 41 (73.2%) | 22 (84.6%) |
| Academic | 12 (21.4%) | 3 (11.5%) |
| Others | 3 (5.4%) | 1 (3.9%) |
| Year of publication | ||
| ~ 2000 | 0 | 0 |
| 2001 ~ 2010 | 24 (42.9%) | 19 (73.1%) |
| 2011 ~ 2020 | 32 (57.1%) | 7 (26.9%) |
| Region | ||
| Europe and North America | 10 (19.6%) | 6 (25.0%) |
| Multiple countries | 27 (52.9%) | 16 (66.7%) |
| Others | 14 (27.5%) | 2 (8.3%) |
| Sample size | ||
| Less than 500 | 37 (66.1%) | 10 (38.5%) |
| 500 and more | 19 (33.9%) | 16 (61.54%) |
| Health care providers | ||
| Funding sources | ||
| Industry | 42 (77.8%) | 24 (88.9%) |
| Academic | 8 (14.8%) | 2 (7.4%) |
| Others | 4 (7.4%) | 1 (3.7%) |
| Year of publication | ||
| ~ 2000 | 0 | 0 |
| 2001 ~ 2010 | 24 (44.4%) | 20 (74.1%) |
| 2011 ~ 2020 | 30 (55.6%) | 7 (25.9%) |
| Region | ||
| Europe and North America | 5 (20.8%) | 6 (12.5%) |
| Multiple countries | 17 (70.8%) | 28 (58.3%) |
| Others | 2 (8.3%) | 14 (29.2%) |
| Sample size | ||
| Less than 500 | 11 (40.7%) | 34 (63.0%) |
| 500 and more | 16 (59.3%) | 20 (37.0%) |
| Outcome assessors | ||
| Funding sources | ||
| Industry | 498 (93.4%) | 305 (93.3%) |
| Academic | 28 (5.3%) | 6 (1.8%) |
| Others | 7 (1.3%) | 16 (4.9%) |
| Year of publication | ||
| ~ 2000 | 2 (0.4%) | 1 (0.3%) |
| 2001 ~ 2010 | 125 (23.5%) | 69 (21.1%) |
| 2011 ~ 2020 | 406 (76.2%) | 257 (78.6%) |
| Region | ||
| Europe and North America | 114 (21.6%) | 47 (15.1%) |
| Multiple countries | 335 (63.6%) | 248 (79.5%) |
| Others | 78 (14.8%) | 39 (12.5%) |
| Sample size | ||
| Less than 500 | 411 (77.1%) | 214 (65.4%) |
| 500 and more | 122 (22.9%) | 113 (34.6%) |